Pharmaceuticals, Biotechnology and Life Sciences
The European Medicines Agency (EMA) has validated and accepted Chinese HUTCHMED Limited’s marketing authorization application (MAA) for surufatinib for the treatment of pancreatic and extra-pancreatic (non-pancreatic) neuroendocrine tumors (NETs).
Hutchison China MediTech Limited said on Friday that it got approval from the China’s authority, the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), a Priority Review status to the New Drug Application (NDA) for surufatinib, for the treatment of patients with advanced non-pancreatic neuroendocrine tumors (NET).